Final results from the BETAPAEDIC study of interferon beta-1b for treatment-naive pediatric patients with relapsing-remitting MS (P1.346)

Conclusions:Final results from BETAPAEDIC suggest that IFNB-1b is an effective treatment with a favorable tolerability profile for pediatric patients with RRMS.Study Supported by: Bayer HealthcareDisclosure: Dr. Gaertner has received personal compensation from Bayer Vital, Biogen, Merck Serono, Teva, and Novartis as a consultant and for honoraria. Dr. Gaertner has received research support from Novartis and Biogen. Dr. Brueck has received personal compensation for activities with Bayer Vital, Biogen, Merck Serono, Teva Pharma, Genzyme, Sanofi Aventis, and Novartis as a lecturer or member of scientific advisory boards. Dr. Weddige has received personal compensation for activities with Bayer Pharma AG. Dr. Hummel has received personal compensation for activities with Bayer Pharma AG as an speaker. Dr. Norenberg has received personal compensation for activities with Bayer Pharma AG. Dr. Bugge has received personal compensation for activities with Bayer Pharma AG as an employee.

Source: Neurology - April 17, 2017 Category: Neurology Authors: Gartner, J., Bruck, W., Weddige, A., Hummel, H., Norenberg, C., Bugge, J.-P. Tags: Pediatric Multiple Sclerosis Source Type: research